NO973551D0 - Indoler med brostruktur som matriksmetallproteaseinhibitorer - Google Patents

Indoler med brostruktur som matriksmetallproteaseinhibitorer

Info

Publication number
NO973551D0
NO973551D0 NO973551A NO973551A NO973551D0 NO 973551 D0 NO973551 D0 NO 973551D0 NO 973551 A NO973551 A NO 973551A NO 973551 A NO973551 A NO 973551A NO 973551 D0 NO973551 D0 NO 973551D0
Authority
NO
Norway
Prior art keywords
indoles
protease inhibitors
bridge structure
matrix metal
metal protease
Prior art date
Application number
NO973551A
Other languages
English (en)
Other versions
NO311257B1 (no
NO973551L (no
Inventor
Arlindo L Castelhano
Teng J Liak
Stephen Horne
Zhengyo Yuan
Alexander Krantz
Jian Jeffrey Chen
Harold Van Wart
Paul D Cannon
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO973551D0 publication Critical patent/NO973551D0/no
Publication of NO973551L publication Critical patent/NO973551L/no
Publication of NO311257B1 publication Critical patent/NO311257B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19973551A 1995-02-03 1997-08-01 Indoler med brostruktur som matriksmetallproteaseinhibitorer, samt farmasöytiske preparater som omfatter dem NO311257B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/382,818 US6013792A (en) 1993-08-05 1995-02-03 Matrix metalloprotease inhibitors
PCT/US1996/001506 WO1996023791A1 (en) 1995-02-03 1996-02-02 Bridged indoles as matrix metalloprotease inhibitors

Publications (3)

Publication Number Publication Date
NO973551D0 true NO973551D0 (no) 1997-08-01
NO973551L NO973551L (no) 1997-10-03
NO311257B1 NO311257B1 (no) 2001-11-05

Family

ID=23510527

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973551A NO311257B1 (no) 1995-02-03 1997-08-01 Indoler med brostruktur som matriksmetallproteaseinhibitorer, samt farmasöytiske preparater som omfatter dem

Country Status (18)

Country Link
US (1) US6013792A (no)
EP (1) EP0807114A1 (no)
JP (1) JPH11500109A (no)
KR (1) KR100403687B1 (no)
CN (1) CN1066150C (no)
AR (1) AR002958A1 (no)
AU (1) AU705763B2 (no)
BR (1) BR9606998A (no)
CA (1) CA2212236A1 (no)
CZ (1) CZ293868B6 (no)
FI (1) FI113965B (no)
HU (1) HUP9702073A3 (no)
NO (1) NO311257B1 (no)
PL (1) PL321659A1 (no)
RU (1) RU2191779C2 (no)
UA (1) UA67716C2 (no)
WO (1) WO1996023791A1 (no)
ZA (1) ZA96850B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
DK0874830T3 (da) * 1995-12-08 2003-04-22 Agouron Pharma Metalloproteinaseinhibitor, farmaceutisk præparat indeholdende denne og den farmaceutiske anvendelse samt en fremgangsmåde til fremstilling deraf
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9715030D0 (en) * 1997-07-18 1997-09-24 British Biotech Pharm Metalloproteinase inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9907055D0 (en) 1999-03-29 1999-05-19 British Biotech Pharm Antibacterial agents
AR032920A1 (es) * 2001-03-01 2003-12-03 Smithkline Beecham Corp Compuestos inhibidores de las peptido-deformilasas y medios para tratar infecciones bacterianas utilizando dichos inhibidores
UY27813A1 (es) * 2002-05-31 2003-12-31 Smithkline Beecham Corp Inhibidores de la peptido-desformilasa
BR0317715A (pt) * 2002-12-27 2005-11-22 Angiotech Int Ag Composições e processos de uso de collajolie
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ATE466953T1 (de) * 2003-01-17 2010-05-15 Advanced Proteome Therapeutics Verfahren zur identifizierung aktivierter polymer-komplexe zur sekundären stellen-spezifischen modifikation von protein ziel-gruppen.
AU2003902115A0 (en) * 2003-05-02 2003-05-22 The University Of Queensland Method of predicting functional outcome of a stroke using eeg measures
WO2005012332A1 (en) * 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
KR100753796B1 (ko) 2006-07-28 2007-08-31 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
UA108596C2 (xx) * 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
CN105801530A (zh) * 2016-04-13 2016-07-27 成都拿盛科技有限公司 一种4位取代的手性γ-丁内酯的合成方法
KR20220105061A (ko) 2021-01-19 2022-07-26 (주)월드트렌드 밀착력과 착용감 향상 및 수시 교체가 가능한 안경테와 코 받침의 조립구조

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
EP0586537A4 (en) * 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
GB9122859D0 (en) * 1991-10-28 1991-12-11 Smithkline Beecham Plc Novel compounds
BR9407217A (pt) * 1993-08-05 1996-09-17 Syntex Inc Inibidores de metaloprotease de matriz

Also Published As

Publication number Publication date
KR100403687B1 (ko) 2004-02-11
CN1066150C (zh) 2001-05-23
AR002958A1 (es) 1998-05-27
AU4863696A (en) 1996-08-21
RU2191779C2 (ru) 2002-10-27
JPH11500109A (ja) 1999-01-06
FI973198A (fi) 1997-08-01
BR9606998A (pt) 1997-10-28
FI973198A0 (fi) 1997-08-01
PL321659A1 (en) 1997-12-22
CZ293868B6 (cs) 2004-08-18
CA2212236A1 (en) 1996-08-08
US6013792A (en) 2000-01-11
ZA96850B (en) 1997-11-03
CN1180358A (zh) 1998-04-29
HUP9702073A3 (en) 1999-05-28
EP0807114A1 (en) 1997-11-19
CZ243197A3 (cs) 1998-01-14
HUP9702073A2 (hu) 1998-03-30
NO311257B1 (no) 2001-11-05
UA67716C2 (en) 2004-07-15
NO973551L (no) 1997-10-03
AU705763B2 (en) 1999-06-03
FI113965B (fi) 2004-07-15
WO1996023791A1 (en) 1996-08-08

Similar Documents

Publication Publication Date Title
NO973551D0 (no) Indoler med brostruktur som matriksmetallproteaseinhibitorer
NO20006716D0 (no) Proteaseinhibitorer
NO990857D0 (no) Fosfinsyreamider som matriks-metallprotease-inhibitorer
NO995433D0 (no) Protease-inhibitorer
NO972307D0 (no) Matriksmetallproteaseinhibitorer
NO975742D0 (no) Reversible cysteinproteasehemmere
MA23800A1 (fr) Nouvelle composition
NO992492D0 (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
NO974403D0 (no) Reversible proteasehemmere
DK0934259T3 (da) Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
NO990856L (no) Spirosykliske metallprotease-inhibitorer
DK0593294T3 (da) Aminderivater som korrosionsinhibitorer
NO995434D0 (no) Proteaseinhibitorer
NO994103D0 (no) Reverse hydroksamatderivater som metallproteaseinhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
ID17792A (id) Penghambat penghambat metaloproreinase matriks
DK0937036T3 (da) Substituerede 4-biphenyl-4-hydroxysmørsyrederivater som matrixmetalprotease-inhibitorer
NO975880L (no) Formylderivater anvendt som ikke-ioniske kontrastmidler
PT1047665E (pt) Inibidores de metaloproteases de matriz
NO962015D0 (no) Pyron-derivater som protease-inhibitorer og antivirus-midler
ID23866A (id) Komposisi untuk menyelamatkan beras terhadap asetoklor
KR960005219U (ko) 점탄성 교량 받침구
KR950014446U (ko) 축대용 블럭고정구
DE69610774T2 (de) Matrix überbrückungs-verbindungsanordnung